Skip to content
lifestyle.healthsourcemag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
GENFIT S.A.
GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
July 2, 2026
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
June 23, 2026
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
June 15, 2026
GENFIT: NASHnext®, Powered by GENFIT’s Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH
June 8, 2026
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026
May 26, 2026
GENFIT Reports First Quarter 2026 Financial Information and Provides a Corporate Update
May 25, 2026
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales
February 13, 2026
←
Previous Page
1
2